Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Adalimumab decreases aortic stiffness independently of its effect in disease activity in patients with rheumatoid arthritis.

Vassilopoulos D, Gravos A, Vlachopoulos C, Kandili A, Ioakeimidis N, Pectasides D, Stefanadis C.

Clin Rheumatol. 2015 Feb;34(2):359-64. doi: 10.1007/s10067-014-2718-8. Epub 2014 Jun 15.

PMID:
24928345
2.

Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases.

Hatzara C, Hadziyannis E, Kandili A, Koutsianas C, Makris A, Georgiopoulos G, Vassilopoulos D.

Ann Rheum Dis. 2015 Oct;74(10):1848-53. doi: 10.1136/annrheumdis-2014-205376. Epub 2014 May 22.

PMID:
24854354
3.

Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection.

Mitroulis I, Hatzara C, Kandili A, Hadziyannis E, Vassilopoulos D.

Ann Rheum Dis. 2013 Feb;72(2):308-10. doi: 10.1136/annrheumdis-2012-202088. Epub 2012 Aug 28. No abstract available.

PMID:
22930597
4.

Comparison of two gamma interferon release assays and tuberculin skin testing for tuberculosis screening in a cohort of patients with rheumatic diseases starting anti-tumor necrosis factor therapy.

Vassilopoulos D, Tsikrika S, Hatzara C, Podia V, Kandili A, Stamoulis N, Hadziyannis E.

Clin Vaccine Immunol. 2011 Dec;18(12):2102-8. doi: 10.1128/CVI.05299-11. Epub 2011 Oct 12.

Supplemental Content

Loading ...
Support Center